Delisted from NASDAQ in May 2022
BFRA - Biofrontera AG
NASDAQ
->
Healthcare
->
Biotechnology
Leverkusen,
Germany
Type: Equity
BFRA price evolution
BFRA
| (in millions $) | 30 Sep 2021 | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $29.54 | $32.62 | $37.33 | $16.55 |
| Short term investments | $1.37 | $1.07 | $0.72 | $0.53 |
| Net receivables | $2.81 | $3.33 | $2.48 | $3.51 |
| Inventory | $4.26 | $3.89 | $4.96 | $4.67 |
| Total current assets | $40 | $43.17 | $46.76 | $26.13 |
| Long term investments | ||||
| Property, plant & equipment | $4.22 | $4.46 | $4.78 | $5.05 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $35.5 | $36.55 | ||
| Total investments | ||||
| Total assets | $69.23 | $72.63 | $77.08 | $56.39 |
| Current liabilities | ||||
| Accounts payable | $3.32 | $2.21 | $2.7 | $1.62 |
| Deferred revenue | ||||
| Short long term debt | $22.62 | $3.19 | $3.15 | $1.14 |
| Total current liabilities | $31.75 | $10.97 | $11.44 | $8.29 |
| Long term debt | $2 | $21.04 | $20.83 | $22.74 |
| Total noncurrent liabilities | $48.3 | $48.23 | ||
| Total debt | ||||
| Total liabilities | $53.33 | $51.06 | $51.44 | $49.02 |
| Shareholders' equity | ||||
| Retained earnings | -$180.4 | -$174.6 | -$170.61 | -$165.73 |
| Other shareholder equity | $2.22 | $2.15 | $2.28 | $1.87 |
| Total shareholder equity | $15.89 | $21.57 | $25.63 | $7.38 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 30 Dec 2017 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $16.55 | $11.12 | $19.45 | $11.08 |
| Short term investments | $0.53 | $1.08 | $0.79 | $0.03 |
| Net receivables | $3.51 | $5.04 | $3.45 | $1.56 |
| Inventory | $4.67 | $4.07 | $3.18 | $3.73 |
| Total current assets | $26.13 | $22.49 | $27.59 | $18.45 |
| Long term investments | ||||
| Property, plant & equipment | $5.05 | $5.23 | $0.79 | $0.75 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $34.57 | $40.18 | $13.64 | $1.58 |
| Total investments | ||||
| Total assets | $56.39 | $58.36 | $39.13 | $19.85 |
| Current liabilities | ||||
| Accounts payable | $1.62 | $4.2 | $1.81 | $1.62 |
| Deferred revenue | ||||
| Short long term debt | $1.14 | $1.21 | $0.17 | |
| Total current liabilities | $8.29 | $11.58 | $7.77 | $4.11 |
| Long term debt | $22.74 | $22.11 | $13.46 | $12.36 |
| Total noncurrent liabilities | $46.53 | $41.25 | $17.72 | $13.96 |
| Total debt | ||||
| Total liabilities | $49.02 | $48.41 | $22.78 | $16.47 |
| Shareholders' equity | ||||
| Retained earnings | -$165.73 | -$152.71 | -$145.38 | -$136.5 |
| Other shareholder equity | $1.87 | -$0.29 | -$0 | $101.47 |
| Total shareholder equity | $7.38 | $9.96 | $16.36 | $3.38 |
| (in millions $) | 30 Sep 2021 | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $5.38 | $7.62 | $5.48 | $9.52 |
| Cost of revenue | $0.7 | $1.11 | $0.9 | $0.97 |
| Gross Profit | $4.68 | $6.5 | $4.58 | $8.55 |
| Operating activities | ||||
| Research & development | $1.59 | $1.6 | $1.32 | $1.39 |
| Selling, general & administrative | $8.08 | $8.39 | $7.35 | $6.41 |
| Total operating expenses | $10.37 | $11.11 | $9.57 | $8.76 |
| Operating income | -$4.99 | -$3.49 | -$4.09 | $0.75 |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.01 | $0.04 | -$0.07 | |
| Interest expense | ||||
| Net income | ||||
| Net income | -$5.8 | -$4 | -$4.88 | -$1 |
| Income (for common shares) | -$5.8 | -$4 | -$4.88 | -$1 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 30 Dec 2017 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $30.35 | $31.27 | $21.11 | $12.03 |
| Cost of revenue | $3.54 | $4.88 | $4.45 | $1.72 |
| Gross Profit | $26.81 | $26.39 | $16.66 | $10.31 |
| Operating activities | ||||
| Research & development | $4.75 | $4.56 | $3.83 | $4.22 |
| Selling, general & administrative | $24.43 | $42.06 | $30.07 | $20.02 |
| Total operating expenses | $37.96 | $39.83 | $39.59 | $25.96 |
| Operating income | -$7.61 | -$8.56 | -$18.48 | -$13.93 |
| Income from continuing operations | ||||
| EBIT | -$13.93 | |||
| Income tax expense | $0.33 | $2.58 | -$10.39 | |
| Interest expense | -$1.13 | |||
| Net income | ||||
| Net income | -$13.02 | -$7.36 | -$8.88 | -$16.1 |
| Income (for common shares) | -$13.02 | -$7.36 | -$8.88 | -$16.1 |
| (in millions $) | 30 Jun 2021 | 30 Mar 2021 | 30 Dec 2020 | 29 Sep 2020 |
|---|---|---|---|---|
| Net income | -$8.84 | -$4.88 | -$1 | -$6.46 |
| Operating activities | ||||
| Depreciation | $1.62 | |||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$5.62 | |||
| Investing activities | ||||
| Capital expenditures | -$0.29 | |||
| Investments | ||||
| Total cash flows from investing | -$0.29 | |||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $24.67 | |||
| Net borrowings | -$0.67 | |||
| Total cash flows from financing | $21.76 | |||
| Effect of exchange rate | $0.22 | |||
| Change in cash and equivalents | $16.08 | |||
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 30 Dec 2017 |
|---|---|---|---|---|
| Net income | -$12.7 | -$4.78 | -$19.27 | -$16.1 |
| Operating activities | ||||
| Depreciation | $5.33 | $3.16 | $0.75 | $0.76 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$2.85 | -$32.89 | -$13.43 | -$13.12 |
| Investing activities | ||||
| Capital expenditures | -$0.77 | -$1.85 | -$0.51 | -$0.4 |
| Investments | ||||
| Total cash flows from investing | $2.87 | $21.05 | -$0.51 | -$0.38 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $8.5 | $0.3 | $24.63 | |
| Net borrowings | -$1.36 | $3.82 | -$0.05 | $9.77 |
| Total cash flows from financing | $5.95 | $3.46 | $22.27 | $9.45 |
| Effect of exchange rate | -$0.55 | $0.05 | $0.04 | $0.04 |
| Change in cash and equivalents | $5.43 | -$8.33 | $8.37 | -$4.04 |
News
|
25 Stocks Moving in Thursday's Pre-Market Session
Benzinga
17 Feb 2022
|
|
Biofrontera Stock Plunges After Announcing Nasdaq Delisting By Investing.com
Investing.com
14 Feb 2022
|
|
52 Biggest Movers From Yesterday
Benzinga
2 Feb 2022
|
|
34 Stocks Moving In Tuesday's Mid-Day Session
Benzinga
1 Feb 2022
|
|
21 Stocks Moving in Tuesday's Pre-Market Session
Benzinga
11 Jan 2022
|
|
60 Biggest Movers From Yesterday
Benzinga
11 Jan 2022
|
|
18 Stocks Moving in Friday's Pre-Market Session
Benzinga
31 Dec 2021
|
|
44 Stocks Moving In Thursday's Mid-Day Session
Benzinga
30 Dec 2021
|
|
12 Healthcare Stocks That Trade At Premium To Their IPO Price
RTT News
28 Dec 2021
|
|
20 Stocks Moving in Wednesday's Pre-Market Session
Benzinga
22 Dec 2021
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 56.72M |
| Revenue | $28.00M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$15.68M |
| Revenue Q/Q | 14.23% |
| Revenue Y/Y | -15.23% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 0.24 |
| Cash/Share | 0.52 |
| EPS | -$0.28 |
|---|---|
| ROA | -22.78% |
| ROE | -89.00% |
| Debt/Equity | 6.64 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.26 |
| Quick ratio | 1.13 |